Johnson & Johnson (JNJ) has strategically shifted its focus from consumer health to its innovative medicine and medtech sectors, following the spin-off of its consumer health business, Kenvue. This transition comes at a crucial time as J&J faces the loss of exclusivity for its top-selling drug, Stelara. Despite this challenge, the company has managed to maintain growth in its core businesses, with shares rising 15% this year, even as the S&P 500 has struggled.
The resilience of J&J’s stock during economic uncertainty highlights the stability of pharma investments, which tend to thrive regardless of market conditions. With 28 products generating over $1 billion annually and a strong commitment to dividend growth—having increased its payout for over 50 years—J&J presents an attractive option for investors seeking reliable income and capital appreciation.
For professionals looking to strengthen their portfolios, J&J stands out as a solid buy and hold. I recommend diving deeper into the full article for a comprehensive analysis of J&J’s market position and future outlook.
Source: fool.com